购物车
- 全部删除
- 您的购物车当前为空
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) 是一款HER2靶向ADC,它通过组织蛋白酶B的识别和裂解作用,选择性地作用于肿瘤细胞。此化合物在子宫和卵巢癌肉瘤等癌症的研究中显示出抗肿瘤活性。
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) 是一款HER2靶向ADC,它通过组织蛋白酶B的识别和裂解作用,选择性地作用于肿瘤细胞。此化合物在子宫和卵巢癌肉瘤等癌症的研究中显示出抗肿瘤活性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 12,000 | 期货 | |
5 mg | 询价 | 期货 |
产品描述 | Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is an ADC targeting HER2 that undergoes cleavage by histone B within tumor cells, thereby achieving selective targeting of these cells. It exhibits antitumor activity and is applicable in cancer research, particularly concerning uterine and ovarian sarcomas [1]. |
体外活性 | Trastuzumab duocarmazine(SYD985)(0.0001-100 μg/mL,24小时内)对HER2-和HER2+细胞都呈现出显著的细胞毒性。与T-DM1对HER2/NEU 3+细胞系的IC50值0.096 μg/mL相比,SYD985的细胞毒性增强了约7倍,IC50值降至0.013 μg/mL。而在HER2/NEU 1+细胞中,SYD985相较T-DM1显示出更高效的杀伤力,其IC50值是后者的54倍[1]。 |
体内活性 | Trastuzumab duocarmazine (SYD985) (3 mg/kg或10 mg/kg,i.v.,单次) 能够有效抑制肿瘤生长,延长小鼠生存时间,显示出显著的体内抗肿瘤效果[1]。 |
别名 | (vic)-Trastuzumab duocarmazine |
CAS No. | 1642152-40-6 |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容